Fig. 4.
Humoral responses to 6PGD and S. aureus pSJH101 6PGD391–410 in humans. a Sera from healthy subjects (n = 23), MPO-AAV (n = 31) and PR3-AAV patients (n = 30) assessed by ELISA for pSJH101-derived recombinant 6PGD. b Sera from healthy subjects (n = 14), MPO-AAV (n = 26) and PR3-AAV patients (n = 24) assessed by ELISA to pSJH101 6PGD391–410. c S. aureus pSJH101 6PGD391–410 inhibits autoantibody binding to human MPO435–454 (the MPO409–428 homolog) in acute MPO-AAV. Serum IgG from patients with acute MPO-AAV (n = 15) were pre-incubated with S. aureus pSJH101 6PGD391–410 then used to detect anti-hMPO435–454 IgG antibodies by ELISA. Values are quintuplicates. Error bars in a and b are mean ± s.d., in panel c mean ± s.e.m. *P < 0.05, **P < 0.01, Mann–Whitney U-test. Source data are provided as a Source Data file